J M Pipas1, B I Zaki2, M M McGowan3, M J Tsapakos4, G H Ripple3, A A Suriawinata5, G J Tsongalis5, T A Colacchio6, S R Gordon7, J E Sutton8, A Srivastava9, K D Smith6, T B Gardner7, M Korc10, T H Davis3, M Preis3, S M Tarczewski11, T A MacKenzie12, R J Barth6. 1. Section Hematology/Oncology, Department of Medicine. Electronic address: J.Marc.Pipas@Hitchcock.org. 2. Section Radiation Oncology, Department of Medicine. 3. Section Hematology/Oncology, Department of Medicine. 4. Department of Radiology. 5. Department of Pathology. 6. Section Surgical Oncology, Department of Surgery. 7. Section Gastroenterology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon. 8. Department of Surgery, Veterans Administration Medical Center, White River Junction. 9. Department of Pathology, Brigham & Women's Hospital, Boston. 10. Department of Medicine, Indiana University School of Medicine, Indianapolis. 11. Office of Clinical Research, Norris Cotton Cancer Center, Lebanon. 12. Department of Epidemiology & Biostatistics, Dartmouth-Hitchcock Medical Center, Lebanon, USA.
Abstract
BACKGROUND: Neoadjuvant therapy has been investigated for localized and locally advanced pancreatic ductal adenocarcinoma (PDAC) but no standard of care exists. Combination cetuximab/gemcitabine/radiotherapy demonstrates encouraging preclinical activity in PDAC. We investigated cetuximab with twice-weekly gemcitabine and intensity-modulated radiotherapy (IMRT) as neoadjuvant therapy in patients with localized or locally advanced PDAC. EXPERIMENTAL DESIGN: Treatment consisted of cetuximab load at 400 mg/m(2) followed by cetuximab 250 mg/m(2) weekly and gemcitabine 50 mg/m(2) twice-weekly given concurrently with IMRT to 54 Gy. Following therapy, patients were considered for resection. RESULTS: Thirty-seven patients were enrolled with 33 assessable for response. Ten patients (30%) manifested partial response and 20 (61%) manifested stable disease by RECIST. Twenty-five patients (76%) underwent resection, including 18/23 previously borderline and 3/6 previously unresectable tumors. Twenty-three (92%) of these had negative surgical margins. Pathology revealed that 24% of resected tumors had grade III/IV tumor kill, including two pathological complete responses (8%). Median survival was 24.3 months in resected patients. Outcome did not vary by epidermal growth factor receptor status. CONCLUSIONS: Neoadjuvant therapy with cetuximab/gemcitabine/IMRT is tolerable and active in PDAC. Margin-negative resection rates are high and some locally advanced tumors can be downstaged to allow for complete resection with encouraging survival. Pathological complete responses can occur. This combination warrants further investigation.
BACKGROUND: Neoadjuvant therapy has been investigated for localized and locally advanced pancreatic ductal adenocarcinoma (PDAC) but no standard of care exists. Combination cetuximab/gemcitabine/radiotherapy demonstrates encouraging preclinical activity in PDAC. We investigated cetuximab with twice-weekly gemcitabine and intensity-modulated radiotherapy (IMRT) as neoadjuvant therapy in patients with localized or locally advanced PDAC. EXPERIMENTAL DESIGN: Treatment consisted of cetuximab load at 400 mg/m(2) followed by cetuximab 250 mg/m(2) weekly and gemcitabine 50 mg/m(2) twice-weekly given concurrently with IMRT to 54 Gy. Following therapy, patients were considered for resection. RESULTS: Thirty-seven patients were enrolled with 33 assessable for response. Ten patients (30%) manifested partial response and 20 (61%) manifested stable disease by RECIST. Twenty-five patients (76%) underwent resection, including 18/23 previously borderline and 3/6 previously unresectable tumors. Twenty-three (92%) of these had negative surgical margins. Pathology revealed that 24% of resected tumors had grade III/IV tumor kill, including two pathological complete responses (8%). Median survival was 24.3 months in resected patients. Outcome did not vary by epidermal growth factor receptor status. CONCLUSIONS: Neoadjuvant therapy with cetuximab/gemcitabine/IMRT is tolerable and active in PDAC. Margin-negative resection rates are high and some locally advanced tumors can be downstaged to allow for complete resection with encouraging survival. Pathological complete responses can occur. This combination warrants further investigation.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Donald J Buchsbaum; James A Bonner; William E Grizzle; Murray A Stackhouse; Mark Carpenter; Daniel J Hicklin; Peter Bohlen; Kevin P Raisch Journal: Int J Radiat Oncol Biol Phys Date: 2002-11-15 Impact factor: 7.038
Authors: J Marc Pipas; Richard J Barth; Bassem Zaki; Michael J Tsapakos; Arief A Suriawinata; Michael A Bettmann; Justin M Cates; Gregory H Ripple; John E Sutton; Stuart R Gordon; Carol E McDonnell; Raymond P Perez; Nancy Redfield; Louise P Meyer; John F Marshall; Bernard F Cole; Thomas A Colacchio Journal: Ann Surg Oncol Date: 2005-11-01 Impact factor: 5.344
Authors: J M Pipas; S E Mitchell; R J Barth; R Vera-Gimon; J Rathmann; L P Meyer; R S Wagman; L D Lewis; C McDonnell; T A Colacchio; R P Perez Journal: Int J Radiat Oncol Biol Phys Date: 2001-08-01 Impact factor: 7.038
Authors: Joseph M Herman; Michael J Swartz; Charles C Hsu; Jordan Winter; Timothy M Pawlik; Elizabeth Sugar; Ray Robinson; Daniel A Laheru; Elizabeth Jaffee; Ralph H Hruban; Kurtis A Campbell; Christopher L Wolfgang; Fariba Asrari; Ross Donehower; Manuel Hidalgo; Luis A Diaz; Charles Yeo; John L Cameron; Richard D Schulick; Ross Abrams Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: Brian A Boone; Jennifer Steve; Alyssa M Krasinskas; Amer H Zureikat; Barry C Lembersky; Michael K Gibson; Ronald G Stoller; Herbert J Zeh; Nathan Bahary Journal: J Surg Oncol Date: 2013-09 Impact factor: 3.454
Authors: Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee Journal: J Gastrointest Surg Date: 2016-10-24 Impact factor: 3.452
Authors: Francesco D'Angelo; Laura Antolino; Alessio Farcomeni; Dario Sirimarco; Andrea Kazemi Nava; Martina De Siena; Niccolò Petrucciani; Giuseppe Nigri; Stefano Valabrega; Paolo Aurello; Giovanni Ramacciato Journal: Med Oncol Date: 2017-04-08 Impact factor: 3.064
Authors: Agata I Rembielak; Pooja Jain; Andrew S Jackson; Melanie M Green; Gillian R Santorelli; Gillian A Whitfield; Adrian Crellin; Angel Garcia-Alonso; Ganesh Radhakrishna; James Cullen; M Ben Taylor; Ric Swindell; Catharine M West; Juan Valle; Azeem Saleem; Patricia M Price Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243
Authors: Timothy B Gardner; Chad C Spangler; Katerina L Byanova; Gregory H Ripple; Matthew J Rockacy; John M Levenick; Kerrington D Smith; Thomas A Colacchio; Richard J Barth; Bassem I Zaki; Michael J Tsapakos; Stuart R Gordon Journal: Gastrointest Endosc Date: 2016-03-10 Impact factor: 9.427